Matthew Ronsheim - 18 Jan 2022 Form 4 Insider Report for Entasis Therapeutics Holdings Inc.

Role
Chief of Pharmaceutical Sciences and Manufacturing
Signature
Elizabeth M. Keiley as Attorney-in-Fact for Matthew Ronsheim
Issuer symbol
N/A
Transactions as of
18 Jan 2022
Net transactions value
$0
Form type
4
Filing time
19 Jan 2022, 15:04:31 UTC
Previous filing
03 Nov 2021
Next filing
11 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ETTX Common Stock Award $0 +125,000 +294% $0.000000 167,572 18 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award vests over four years with twenty-five percent of the award vesting on each anniversary of the date of grant, subject to the reporting person's continued employment with the Company.

Remarks:

Chief of Pharmaceutical Sciences and Manufacturing